Viewing Study NCT04896203


Ignite Creation Date: 2025-12-24 @ 7:35 PM
Ignite Modification Date: 2025-12-31 @ 12:00 AM
Study NCT ID: NCT04896203
Status: UNKNOWN
Last Update Posted: 2021-07-23
First Post: 2020-11-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Hypercoagulability Study Using Haemostatic Techniques in Patients With Inflammatory Bowel Disease
Sponsor: Hospital Universitario La Paz
Organization:

Study Overview

Official Title: Hypercoagulability Study Using Haemostatic Techniques in Patients With Inflammatory Bowel Disease
Status: UNKNOWN
Status Verified Date: 2021-07
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: EDGAR
Brief Summary: Descriptive study, in which the haemostatic profile of ambulatory patients with IBD will be analyzed by means of ROTEM and other techniques, such as the thrombin generation test and the study of platelet function by flow cytometry.
Detailed Description: Descriptive study, in which the haemostatic profile of ambulatory patients with IBD will be analyzed by rotational thromboelastometry (ROTEM) and other techniques, such as thrombin generation test and platelet function study by flow cytometry. The results of these measurements will be subsequently compared between the different IBD patient groups, stratified by activity and other risk factors, as well as with healthy controls, in order to define in which of these situations a significant prothrombotic risk exists, and which part of the coagulation cascade conditions that risk. After this, we will describe the incidence and prevalence of thromboembolic events in the follow-up of these patient groups. Finally, an attempt will be made to determine, according to the results of the study if any of the situations outside the classic recommendations would be subsidiary to receive chemoprophylaxis for the thromboembolic events.

The aim of this study is to determine the possible state of hypercoagulability of ambulatory patients with Inflammatory Bowel Disease, stratified according to the characteristics of their disease, by using ROTEM as well as the thrombin generation test. Platelet function will also be evaluated by flow cytometry.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: